India’s largest drugmaker Sun Pharmaceutical Industries Ltd has annouced that FDA is planning to lift a ban on its Mohali plant.
The plant in northern India was aquired by Sun as part of the deal with Ranbaxy Laboratories in 2015.
Since its acqusition Sun has worked hard to fix quality control problems found back in 2013 by FDA.
The ban lift will allow Sun Pharmaceutical to restart supplies from there after four years: “This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements,” the company said in a statement to stock exchanges.
Sun’s shares were up 6 percent at 722 rupees at 822 GMT in Mumbai on the day the annoucement came out.
Source: CNBC, Financial Times, Reuters, Bloomberg